EU regulator's committee backs Lilly's Foundayo weight-loss pill
The EMA's committee recommended approval of Lilly's oral weight-loss drug Foundayo, the second such pill after Novo Nordisk's Wegovy. Final EU decision pending.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
The European Medicines Agency's committee recommended approving Foundayo from Eli Lilly for weight management and type 2 diabetes treatment in adults, according to TradingView. Approval still requires a final decision from the European Commission, which will examine the committee's advice before Lilly can start sales.
Foundayo becomes the second oral obesity drug to receive the agency's support, following Novo Nordisk's Wegovy pill, which won EU clearance in July. Both companies are competing for a larger slice of a market that is expected to top $100 billion by 2030.
why it matters
For Lilly and Novo, oral treatments have become a new front in the wider competition over obesity drugs. Pills could widen access to treatment, so the pace of approvals in Europe matters for both companies' revenue outlooks.
market impact
LLY, NVO: approval intensifies competition in the obesity pill segment and weighs on both companies' shares
tags
instruments
sources
- Eli Lilly's weight-loss pill wins EU drug regulator's backing — ru.tradingview.com, 16 October 2026 at 10:24 UTC
- Lilly wins EU backing for Foundayo weight-loss pill — seekingalpha.com, 16 October 2026 at 10:41 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗